Abstract
Since the identification of DNA as the hereditary material, therapeutic advancements have focused on gene therapy (GT) and allogeneic hematopoietic cell transplants for inherited diseases. Despite successes in treating conditions like β-thalassemia and sickle cell disease, challenges such as insertional oncogenesis and immunogenicity persist. Future efforts must prioritize improving vector safety, refining manufacturing processes, and expanding access to GT to fully realize its potential.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
